Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. (NYSE: GRDN) is a long-term care pharmacy services company based in Atlanta, Georgia. This news page aggregates company-issued updates and market-facing announcements so readers can follow how Guardian communicates about its operations, growth, and financial performance over time.
In its public news releases, Guardian highlights its role as one of the nation’s leading long-term care pharmacy services companies, partnering with long-term care facilities to deliver medications and technology-enabled services that are designed to improve adherence to drug regimens and support better clinical outcomes. The company frequently reports on revenue trends, resident counts, and Adjusted EBITDA as part of its quarterly financial results and outlook.
Typical news items for GRDN include quarterly earnings releases, guidance updates, and preliminary financial outlooks, such as reiterations of revenue and Adjusted EBITDA guidance and commentary on expected growth trajectories. Guardian also issues announcements about acquisitions and new pharmacy openings, including transactions that expand its presence into new states or strengthen its footprint in existing regions.
Investors and observers can also find capital markets updates in Guardian’s news, such as information about secondary offerings of Class A common stock, shelf registration statements on Form S-3, and lock-up agreements with pre-IPO stockholders. In addition, the company regularly announces participation in healthcare and investor conferences, where it hosts investor meetings and presentations.
By reviewing the GRDN news feed on this page, readers can track Guardian Pharmacy Services’ reported financial results, expansion activities, and other material communications disclosed through press releases and related announcements.
Guardian Pharmacy Services (NYSE: GRDN) priced an upsized underwritten public offering of 6,000,000 Class A shares at $31.00 per share, expected to close on March 20, 2026. 4,980,000 shares are being sold by selling stockholders and 1,020,000 shares are a synthetic secondary to be repurchased by Guardian.
Underwriters have a 30‑day option for up to an additional 900,000 shares. Guardian will not retain net proceeds from selling stockholders and expects the repurchases to complete by March 24, 2026.
Guardian Pharmacy Services (NYSE: GRDN) launched a proposed underwritten public offering of 5,000,000 Class A shares on March 18, 2026, including 3,980,000 shares by selling stockholders and 1,020,000 newly issued shares by Guardian.
The underwriters have a 30-day option for up to an additional 750,000 shares. Guardian intends a non-dilutive "Synthetic Secondary": net proceeds it receives will be used to repurchase an equal number of Class A shares, keeping total outstanding Class A shares unchanged. A shelf registration on Form S-3 became effective November 3, 2025.
Guardian Pharmacy Services (NYSE: GRDN) reported Q4 2025 revenue of $397.6M (+17% YoY; organic +12%) and Q4 Adjusted EBITDA of $39.5M (+53% YoY). Full-year 2025 revenue was $1.45B (+18%); Adjusted EBITDA $115.1M (+27%); net income $49.0M versus a ($71.0M) loss in 2024. Cash totaled $65.6M at year-end. The company raised 2026 Adjusted EBITDA guidance to $120M–$124M while maintaining the prior 2026 revenue outlook of $1.40B–$1.42B. Operational highlights included one acquisition, improved vaccine profitability, and ~205,000 residents served at year-end.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
CEO Fred Burke and CFO David Morris will take part in a fireside chat on Monday, March 16, 2026 at 10:40 a.m. ET. A live audio webcast and a replay available for 90 days will be hosted on the company investor site.
Guardian Pharmacy Services (NYSE: GRDN) will present at the Raymond James Institutional Investors Conference in Orlando on Monday, March 2, 2026 at 1:40 p.m. ET. A live audio webcast will be available via the company's investor site, with a replay accessible shortly after the event for 90 days.
Guardian Pharmacy Services (NYSE: GRDN) will release fourth quarter and full‑year 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss results.
The call is available via audio webcast at the company's investor site and by dialing the provided U.S. and international numbers; a replay will be available shortly after the call and remain online for approximately 60 days.
Guardian Pharmacy Services (NYSE: GRDN) reiterated its 2025 guidance and issued initial 2026 outlook ahead of its J.P. Morgan Healthcare Conference presentation on January 14, 2026. The company reaffirmed 2025 revenue guidance of $1.43B–$1.45B and adjusted EBITDA of $104M–$106M. For 2026 Guardian expects revenue of $1.40B–$1.42B after Inflation Reduction Act drug price reductions and WAC cuts, and adjusted EBITDA of $115M–$118M (~11% growth vs. 2025 guidance) with adjusted EBITDA margin above 8%. The company also completed a single-location pharmacy acquisition in Montana to add a new territory.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026. The company’s leadership will host investor meetings that day and deliver a presentation at 4:30 p.m. PT. A live audio webcast will be available at https://investors.guardianpharmacy.com, with a replay posted shortly after the presentation and available for 30 days.
Guardian Pharmacy Services (NYSE: GRDN) reported third quarter 2025 results and raised full-year guidance. Q3 revenue was $377.4M (+20% YoY) and Adjusted EBITDA was $27.3M (vs. $23.0M). Net income was $9.6M vs. a $(105.8)M loss year-ago. Residents served were ~204,000 (+13% YoY). Diluted EPS was $0.15 with Adjusted EPS of $0.25. Cash totaled $36.5M and there was no long-term debt outstanding under the credit facility.
Guardian raised FY2025 guidance to $1.43B–$1.45B revenue and $104M–$106M Adjusted EBITDA (excludes future acquisitions). Operationally, Guardian closed an acquisition in Oregon to enter the Pacific Northwest. A Form S-3 shelf was filed allowing potential issuance/resale of Class A shares.
Guardian Pharmacy Services (NYSE: GRDN) will participate in the Stephens Investment Conference in Nashville, TN on Wednesday, November 19, 2025. The company will host investor meetings and Fred Burke, co-founder and CEO, will appear in a fireside chat at 11:00 a.m. CT (12:00 p.m. ET). A live audio webcast will be available at the company investor site and a replay will be accessible shortly after the event for 90 days.